WO2017064558A8 - 新規免疫賦活化剤 - Google Patents

新規免疫賦活化剤 Download PDF

Info

Publication number
WO2017064558A8
WO2017064558A8 PCT/IB2016/001543 IB2016001543W WO2017064558A8 WO 2017064558 A8 WO2017064558 A8 WO 2017064558A8 IB 2016001543 W IB2016001543 W IB 2016001543W WO 2017064558 A8 WO2017064558 A8 WO 2017064558A8
Authority
WO
WIPO (PCT)
Prior art keywords
immunostimulant
novel
novel immunostimulant
tetrahydropyrimido
indolizin
Prior art date
Application number
PCT/IB2016/001543
Other languages
English (en)
French (fr)
Other versions
WO2017064558A1 (ja
Inventor
和孝 宮寺
智史 深谷
芳美 青柳
Original Assignee
大鵬薬品工業株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2016148854A external-priority patent/JP2017075137A/ja
Application filed by 大鵬薬品工業株式会社 filed Critical 大鵬薬品工業株式会社
Publication of WO2017064558A1 publication Critical patent/WO2017064558A1/ja
Publication of WO2017064558A8 publication Critical patent/WO2017064558A8/ja

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

この発明は、下記の式(I)で表される(S)-N(4-アミノ-5-(キノリン-3-イル)-6,7,8,9-テトラヒドロピリミド[5,4-b]インドリジン-8-イル)アクリルアミドまたはその塩を有効成分として含有する免疫賦活化剤、および免疫賦活化により改善することができる疾患を予防または治療するための医薬組成物に関する。
PCT/IB2016/001543 2015-10-14 2016-10-28 新規免疫賦活化剤 WO2017064558A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2015-203282 2015-10-14
JP2015203282 2015-10-14
JP2016-148854 2016-07-28
JP2016148854A JP2017075137A (ja) 2015-10-14 2016-07-28 新規免疫賦活化剤

Publications (2)

Publication Number Publication Date
WO2017064558A1 WO2017064558A1 (ja) 2017-04-20
WO2017064558A8 true WO2017064558A8 (ja) 2017-08-17

Family

ID=58517074

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/001543 WO2017064558A1 (ja) 2015-10-14 2016-10-28 新規免疫賦活化剤

Country Status (1)

Country Link
WO (1) WO2017064558A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
CN115607573B (zh) * 2022-12-16 2023-05-23 北京大学第三医院(北京大学第三临床医学院) 一种用于调节杀伤性t细胞活性的方法、药物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
ES2580530T3 (es) * 2012-02-23 2016-08-24 Taiho Pharmaceutical Co., Ltd. Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo
US20150079079A1 (en) * 2013-09-13 2015-03-19 Wake Forest University Health Sciences Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders

Also Published As

Publication number Publication date
WO2017064558A1 (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
WO2017100726A8 (en) Methods for treating huntington's disease
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
WO2017070616A3 (en) Sexually transmitted disease vaccines
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
WO2016105525A3 (en) Novel pyrimidines as egfr inhibitors and methods of treating disorders
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
WO2016011306A3 (en) Terminal modifications of polynucleotides
WO2016130920A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015001504A3 (en) Antibody formulations and methods
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
PH12016500814B1 (en) Heteroaryl butanoic acid derivatives
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
WO2015191945A3 (en) Solid state forms of sofosbuvir
EP3034082A4 (en) Pharmaceutical composition for treating or preventing neuropsychitric disease, containing flavone-6-c-glucose derivatives as active ingredients
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
EP3231436A4 (en) Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient
WO2016011049A3 (en) Compositions and methods for disease treatment using nanoparticle delivered compounds
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
EP3352750A4 (en) Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
PH12016502568B1 (en) Novel heterocyclic compound
EP3311817A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF EYES DISEASES WITH IMATINIB AS AN ACTIVE SUBSTANCE
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16855012

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16855012

Country of ref document: EP

Kind code of ref document: A1